Crizotinib (Xalkori, Pfizer; PF0234066), a tyrosine kinase inhibitor with efficacy against ALK [3], c-MET [4] and ROS1 [5] kinase, has demonstrated superior efficacy over chemotherapy in the first line systemic treatment of advanced ALK-rearranged NSCLC and represents standard of care for this patient population [6]. This evidence concerns the gene ALK and non-small cell lung carcinoma.